Drug Trial Radar · NCT04516746
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
Last checked: Nov 20, 2026Latest source record: Feb 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32,450
Actual
Start
Aug 28, 2020
Primary completion
Mar 5, 2021
Study completion Feb 10, 2023
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd
- First posted
- Aug 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.
Conditions
- COVID-19
- SARS-CoV-2
Interventions
AZD1222Biological
AZD1222 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2-5 surface glycoprotein.
PlaceboBiological
Commercially available 0.9% (n/V) saline for injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Binary ResponseTime frame: From 15 days post second dose up to data cut-off date (DCO) of 05 March 2021 or study discontinuation or unblinding or receipt of non-study COVID-19 vaccination, up to a maximum of 17 weeks
- Number of Participants With Adverse Events (AEs) Post Each Dose of Study InterventionTime frame: From Day 1 up to 28 days post second dose of study intervention, approximately 57 days
- Number of Participants With Serious Adverse Events (SAE), Medically Attended Adverse Events (MAAE), and Adverse Event of Special Interest (AESI) Prior to Non-study COVID-19 VaccinationTime frame: From Day 1 up to receipt of non-study COVID-19 vaccination or a maximum of Day 760 for participants without non-study COVID-19 vaccination.
- Number of Participants With Local and Systemic Solicited AEs in the Substudy OnlyTime frame: From Day 1 up to 7 days post each dose of study intervention, approximately 14 days
Locations
84 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Scottsdale, Arizona
Research Site
Little Rock, Arkansas
Research Site
Berkeley, California
Research Site
El Centro, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
San Diego, California
Research Site
San Diego, California
Research Site
San Francisco, California
Research Site
San Francisco, California
Research Site
Torrance, California
Research Site
Denver, Colorado
Research Site
Danbury, Connecticut
Research Site
Coral Gables, Florida
Research Site
Lake Worth, Florida
Research Site
Miami Lakes, Florida
Research Site
Orlando, Florida
Research Site
Honolulu, Hawaii
Research Site
Meridian, Idaho
Research Site
Chicago, Illinois
Research Site
Indianapolis, Indiana
Research Site
Ankeny, Iowa
Research Site
Fairway, Kansas
Research Site
Kansas City, Kansas
Research Site
Wichita, Kansas
Research Site
Wichita, Kansas
Research Site
Lexington, Kentucky
Research Site
Lake Charles, Louisiana
Research Site
Monroe, Louisiana
Research Site
Baltimore, Maryland
Research Site
Baltimore, Maryland
Research Site
Bethesda, Maryland
Research Site
Boston, Massachusetts
Research Site
Boston, Massachusetts
Research Site
Ann Arbor, Michigan
Research Site
Royal Oak, Michigan
Research Site
Minneapolis, Minnesota
Research Site
Gulfport, Mississippi
Research Site
Butte, Montana
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.